Ahead of print
Research paper
Published online: 2024-04-08
Monocyte-to-lymphocyte ratio is a prognostic predictor for patients with non-small cell lung cancer treated with stereotactic body radiation therapy
Abstract
Background: The monocyte-to-lymphocyte ratio (MLR), a systemic inflammation biomarker, has been shown to predict patient outcomes in several types of cancer. This study aimed to determine the association between MLR and local control (LC) and cause-specific survival (CSS) rates in patients with non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT).
Materials and methods: The median age of the 194 included participants (144 men, 50 women) was 80 (range, 50–96) years. The median follow-up period was 19 (range, 1–108) months. The LC and CSS rates were calculated using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazard regression models were used to estimate the LC and CSS rates.
Results: Local recurrence was observed in 25 patients during the follow-up. Univariate Cox proportional hazards regression analysis revealed that MLR, performance status, and tumor diameter were significant factors for LC. Multivariate analysis showed MLR and tumor diameter as significant factors (p = 0.041 and 0.031, respectively). The 1- and 2-year LC rates for the lower and higher MLR groups were 97.5% and 97.5%, and 89.7% and 81.2%, respectively. During the follow-up period, 14 patients died due to NSCLC. Although MLR tended to predict CSS in univariate analysis (p = 0.086), none of the parameters was significant in predicting CSS. However, MLR as a continuous variable was a significant factor for CSS in the univariate analysis (p = 0.004).
Conclusions: Our data suggest that MLR is correlated with LC and CSS rates in NSCLC patients treated with SBRT.
Keywords: non-small cell lung cancerstereotactic body radiation therapysystemic inflammation biomarker
References
- World Health Organization. CANCER TODAY. https://gco.iarc.fr/today/home.
- National Comprehensive Cancer Network. NCCN Guidelines. Treatment by Cancer Type. Non-Small Cell Lung Cancer. Version 1.2022. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450.
- Paoletti L, Ceccarelli C, Menichelli C, et al. Special stereotactic radiotherapy techniques: procedures and equipment for treatment simulation and dose delivery. Rep Pract Oncol Radiother. 2022; 27(1): 1–9.
- Falcinelli L, Menichelli C, Casamassima F, et al. Stereotactic radiotherapy for lung oligometastases. Rep Pract Oncol Radiother. 2022; 27(1): 23–31.
- Yin Y, Zhang Y, Li Li, et al. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio and Development of a Nomogram in Breast Cancer Patients. Front Oncol. 2021; 11: 650980.
- Chen Y, Sun J, Hu D, et al. Predictive Value of Pretreatment Lymphocyte-to-Monocyte Ratio and Platelet-to-Lymphocyte Ratio in the Survival of Nasopharyngeal Carcinoma Patients. Cancer Manag Res. 2021; 13: 8767–8779.
- Sharaiha RZ, Halazun KJ, Mirza F, et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011; 18(12): 3362–3369.
- Absenger G, Szkandera J, Pichler M, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer. 2013; 109(2): 395–400.
- Botta C, Barbieri V, Ciliberto D, et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther. 2013; 14(6): 469–475.
- Giuliani M, Sampson LR, Wong O, et al. Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes on outcomes in lung stereotactic body radiotherapy. Curr Oncol. 2016; 23(4): e362–e368.
- Luo H, Ge H, Cui Y, et al. Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience. J Cancer. 2018; 9(1): 182–188.
- Matsuo Y, Shibuya K, Nagata Y, et al. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011; 79(4): 1104–1111.
- Tanaka H, Hayashi S, Hoshi H. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy. Asia Pac J Clin Oncol. 2016; 12(1): e113–e117.
- Tanaka H, Ono T, Manabe Y, et al. Anemia is a Prognostic Factor for Overall Survival Rate in Patients with Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy. Cancer Manag Res. 2021; 13: 7447–7453.
- Hanazawa H, Takahashi S, Shiinoki T, et al. Clinical assessment of coiled fiducial markers as internal surrogates for hepatocellular carcinomas during gated stereotactic body radiotherapy with a real-time tumor-tracking system. Radiother Oncol. 2017; 123(1): 43–48.
- Wu XB, Hou SL, Liu Hu. Systemic immune inflammation index, ratio of lymphocytes to monocytes, lactate dehydrogenase and prognosis of diffuse large B-cell lymphoma patients. World J Clin Cases. 2021; 9(32): 9825–9834.
- Hemond CC, Glanz BI, Bakshi R, et al. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurol. 2019; 19(1): 23.
- Wang J, Lin J, Wang M, et al. High Dose Steroids as First-Line Treatment Increased the Risk of In-Hospital Infections in Patients With Anti-NMDAR Encephalitis. Front Immunol. 2021; 12: 774664.
- Yu Y, Wang S, Wang P, et al. Predictive value of lymphocyte-to-monocyte ratio in critically Ill patients with atrial fibrillation: A propensity score matching analysis. J Clin Lab Anal. 2022; 36(2): e24217.
- Zhai B, Chen J, Wu J, et al. Predictive value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score and lymphocyte-to-monocyte ratio (LMR) in patients with non-small cell lung cancer after radical lung cancer surgery. Ann Transl Med. 2021; 9(12): 976.
- Ramos R, Macía I, Navarro-Martin A, et al. Prognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung cancer surgery. BMC Pulm Med. 2021; 21(1): 75.
- Jiang G, Huang J, Cui T, et al. A biomarker-based prediction model for risk of locoregional recurrence in pathologic stage IIIA-N2 non-small cell lung cancer. Int J Clin Exp Pathol. 2020; 13(12): 3060–3082.
- Minami S, Ihara S, Komuta K. Pretreatment Lymphocyte to Monocyte Ratio as a Prognostic Marker for Advanced Pulmonary Squamous Cell Carcinoma Treated With Chemotherapy. J Clin Med Res. 2018; 10(8): 657–664.
- Zahran AM, Hetta HF, Zahran ZA, et al. Prognostic Role of Monocytic Myeloid-Derived Suppressor Cells in Advanced Non-Small-Cell Lung Cancer: Relation to Different Hematologic Indices. J Immunol Res. 2021; 2021: 3241150.
- Guo M, Li W, Li B, et al. Prognostic value of delta inflammatory biomarker-based nomograms in patients with inoperable locally advanced NSCLC. Int Immunopharmacol. 2019; 72: 395–401.
- Yang H, Wang K, Li B, et al. The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy. Front Oncol. 2021; 11: 707041.
- Jin J, Yang L, Liu D, et al. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Lung Cancer: A Systematic Review and Meta-Analysis. Technol Cancer Res Treat. 2021; 20: 1533033820983085.
- Cannon NA, Meyer J, Iyengar P, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol. 2015; 10(2): 280–285.
- Shaverdian N, Veruttipong D, Wang J, et al. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Clin Lung Cancer. 2016; 17(1): 39–46.
- Shi S, Ye L, Zhao Q, et al. Prognostic index score predicts outcome of patients with Stage I non-small cell lung cancer after stereotactic body radiation therapy. Jpn J Clin Oncol. 2019; 49(4): 367–372.
- Leeman JE, Rimner A, Montecalvo J, et al. Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017; 97(1): 138–145.
- Petty AJ, Owen DH, Yang Y, et al. Targeting Tumor-Associated Macrophages in Cancer Immunotherapy. Cancers (Basel). 2021; 13(21).
- Sedighzadeh SS, Khoshbin AP, Razi S, et al. A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications. Transl Lung Cancer Res. 2021; 10(4): 1889–1916.
- Genova C, Dellepiane C, Carrega P, et al. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Front Immunol. 2021; 12: 799455.
- Marceaux C, Weeden CE, Gordon CL, et al. Holding our breath: the promise of tissue-resident memory T cells in lung cancer. Transl Lung Cancer Res. 2021; 10(6): 2819–2829.